UCBJY Company Profile and Key Details

Q: Who are the executives of UCBJY?

Prof. Iris Low-FriedrichExecutive Vice President, Chief Medical Officer and Head of Devel. & Medical Patient Value PracticesMr. Jean-Luc FleurialExecutive Vice President & Chief HR OfficerMs. Kirsten Lund-JurgensenExecutive Vice President of Supply & Technology SolutionsMr. Jean-Christophe TellierChief Executive Officer & Executive DirectorMr. William J. SilbeyExecutive Vice President & Gen. CounselDr. Dhavalkumar D. Patel M.D., Ph.D.Executive Vice President & Chief Scientific OfficerMs. Denelle J. Waynick Johnson J.D.Executive Vice President & Gen. CounselMs. Caroline VancoillieChief Accounting Officer, Head of Group Fin. & Chief Financial Officer of Patient Value FunctionsMr. Charl van ZylExecutive Vice President of Neurology Solutions & Head of EU/InternationalAntje WitteHead of Investor RelationsMs. Sandrine Dufour CFAExecutive Vice President & Chief Financial Officer & Chief Corporation Devel.Mr. Emmanuel CaeymaexExecutive Vice President of Immunology Solutions & Head of US

PNK : UCBJY

UCB SA

$73.15

-0.06-0.08%

At Close 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

UCB S.A. (UCBJY) stock declined over -0.70%, trading at $143.13 on OTC, down from the previous close of $144.14. The stock opened at $144.79, fluctuating between $140.78 and $144.79 in the recent session.

Stock Snapshot

144.14

Prev. Close

54.49B

Market Cap

140.78

Day Low

30.78

P/E Ratio

4.65

EPS (TTM)

2.96

Cash Flow per Share

144.79

Open

380.72M

Number of Shares

144.785

Day High

31.41%

Free Float in %

47.29

Book Value

4.91K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 18, 2026	144.79	144.79	140.75	143.13	22.35K
Jun 17, 2026	144.65	146.80	143.95	144.09	72.47K
Jun 16, 2026	145.86	147.14	144.62	144.94	36.27K
Jun 15, 2026	150.53	151.47	149.87	150.09	33.11K
Jun 12, 2026	157.44	160.08	157.07	158.72	12.7K
Jun 11, 2026	153.63	158.85	153.53	158.01	15.09K
Jun 10, 2026	151.95	153.39	151.52	151.73	12.71K
Jun 09, 2026	151.16	153.05	150.60	151.74	18.29K
Jun 08, 2026	149.59	151.61	148.79	150.16	87.45K
Jun 05, 2026	151.28	152.13	149.37	149.54	25.18K
Jun 04, 2026	149.22	151.53	149.22	150.71	31.74K
Jun 03, 2026	144.82	146.64	144.82	146.18	2.34K
Jun 01, 2026	148.14	149.64	147.29	148.41	45.93K
May 29, 2026	145.67	146.97	145.32	146.42	56.93K
May 28, 2026	141.12	142.52	141.12	142.36	30.32K
May 27, 2026	144.35	144.59	141.22	141.92	23K
May 26, 2026	140.98	142.12	140.98	142.12	29.08K
May 22, 2026	140.60	140.66	139.64	140.35	42.15K
May 21, 2026	138.32	140.93	138.32	140.93	17.39K
May 20, 2026	138.26	139.35	137.89	138.77	19.73K

Contact Details

Brussels, 1070

Belgium

https://www.ucb.com 322 559 9999

About Company

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 CMXHF

CSL Limited$192.00 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 ELOX

0.05+0.36%

Eloxx Pharmaceuticals, Inc.$13.98 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

UCB S.A. (OTC:UCBJY) closed at $143.13 USD, losing -$1.01 (-0.70%) from the previous close of $144.14. The stock is currently mid-range between its 52-week high and low $90.31 and $168.76. With a market capitalization of about $54.49 billion, UCB S.A. is classified as a large-cap and shows lower-than-market volatility (beta ~0.18). Key stats such as the average daily volume over the past year has been around 41.36 thousand shares, volume is running light vs its 52-week average. Headquartered in Brussels, None, UCB S.A. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jean-Christophe Tellier, the company employs approximately 9,052 people and listed since August 03, 2012. UCB S.A.

Technical Performance

Average 10-day trading volume of 27.87 thousand shares is below the 3-month average of 40.48 thousand, indicating normal recent market interest.

Valuation Metrics

UCB SA trades at a P/E ratio of 30.68, slightly below the S&P 500 average, with a price-to-sales ratio of 6.17 and a price-to-book ratio of 4.38 trading at moderately above to book value. The P/FCF stands at 24.08, also above market averages.

Dividend & Fair Value

UCB S.A. last paid a dividend of 0.85 per share, this equals a trailing yield of roughly 1.78%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $143.08. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

UCB SA earnings surprise history is a mixed track record. The quarter that ended February 26, 2026, missed forecasts by 30.24%. The prior quarter beat by -25.39%. Over the last six quarters, Apple has recorded several small beats. These include -75.92% in June 12, 2024.

Financial & Profitability Overview

Over the trailing twelve months, UCB SA generated $5.25B in revenue, or $26.91 per share. Gross margin was 67.50%, operating margin 11.50%, and net profit margin 6.53%. Returns are modest, with ROA at 2.21% and ROE at 3.82%.
On valuation metrics, UCB SA trades at a P/E of 30.59, P/S of 6.16 and P/B of 4.37. The current ratio is 1.38 and quick ratio is 1.04. Operationally, the company’s inventory turnover is 1.41 and cash conversion cycle is -340.30 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.21, supported by a cash flow-to-debt ratio of 1.01.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, UCB SA posted revenue of $5.25B, down slightly from $5.52B in the prior quarter. Gross profit was $3.55B (margin 67.50%). Operating income was $604.00M (margin 11.5%). Net income was$343.00M (EPS $1.81).
The company ended the quarter with $1.06B in cash and short-term investments, a total debt of $3.04B, and net debt of $2.18B. Total assets were $15.54B, with equity of $8.98B. Financials further reflected stability, with operating cash flow of $761.00M, free cash flow of $445.00M, and capital expenditures of - $316.00M.

Price Forecast & Outlook

Our AI price prediction model suggests that UCB SA stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows UCB SA trading at a premium to the broader market with a P/E of 30.68.

Frequently Asked Questions

What is the current UCB SA (UCBJY) stock price?

UCB SA (OTC: UCBJY) stock price is $143.13 in the last trading session. During the trading session, UCBJY stock reached the peak price of $144.79 while $140.78 was the lowest point it dropped to. The percentage change in UCBJY stock occurred in the recent session was -0.7% while the dollar amount for the price change in UCBJY stock was - $1.01.

UCBJY's industry and sector of operation?

The OTC listed UCBJY is part of Biotechnology industry that operates in the broader Healthcare sector. UCB SA designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of UCBJY?

Prof. Iris Low-Friedrich
Executive Vice President, Chief Medical Officer and Head of Devel. & Medical Patient Value Practices
Mr. Jean-Luc Fleurial
Executive Vice President & Chief HR Officer
Ms. Kirsten Lund-Jurgensen
Executive Vice President of Supply & Technology Solutions
Mr. Jean-Christophe Tellier
Chief Executive Officer & Executive Director
Mr. William J. Silbey
Executive Vice President & Gen. Counsel
Dr. Dhavalkumar D. Patel M.D., Ph.D.
Executive Vice President & Chief Scientific Officer
Ms. Denelle J. Waynick Johnson J.D.
Executive Vice President & Gen. Counsel
Ms. Caroline Vancoillie
Chief Accounting Officer, Head of Group Fin. & Chief Financial Officer of Patient Value Functions
Mr. Charl van Zyl
Executive Vice President of Neurology Solutions & Head of EU/International
Antje Witte
Head of Investor Relations
Ms. Sandrine Dufour CFA
Executive Vice President & Chief Financial Officer & Chief Corporation Devel.
Mr. Emmanuel Caeymaex
Executive Vice President of Immunology Solutions & Head of US

How UCBJY did perform over past 52-week?

UCBJY's closing price is 109.9% higher than its 52-week low of $90.31 where as its distance from 52-week high of $168.76 is -0.23%.

How many employees does UCBJY have?

Number of UCBJY employees currently stands at 9,052.

Link for UCBJY official website?

Official Website of UCBJY is: https://www.ucb.com

How do I contact UCBJY?

UCBJY could be contacted at phone 322 559 9999 and can also be accessed through its website. UCBJY operates from Allée de la Recherche, 60, Brussels, 1070, Belgium.

How many shares of UCBJY are traded daily?

UCBJY stock volume for the day was 4.91K shares. The average number of UCBJY shares traded daily for last 3 months was 41.36K.

What is the market cap of UCBJY currently?

The market value of UCBJY currently stands at $54.49B with its latest stock price at $143.13 and 380.72M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	9052
Beta	0.26
Sales or Revenue	$5.25B
5Y Sales Change%	0.127%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

UCBJY Company Profile and Key Details

UCB SA

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Price Forecast & Outlook

Key Takeaways

Financial & Profitability Overview

Quarterly Financial Highlights